Received May 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | Y008282 | IM / LL |
On February 25, 2025, patient received vaccinations in his left leg. Subsequently, he developed a rash on the left leg, which began on March 11, 2025. The rash has progressively enlarged and is associated with itching. patient has been scratching the area, leading to scratch marks. The rash became noticeable with red cheeks and ears on March 17, 2025, followed by a full-body rash on March 18, 2025, which lasted until March 21, 2025, before diminishing. There is some drainage from a particular spot on the rash, and the area underneath the skin has become hard. Patient has not experienced any fevers and continues his regular activities. He is aware of the rash and finds it bothersome. There is no history of eczema or similar rashy conditions. Patient is two years post-bone marrow transplant and is not on any active oncology treatments.
SCID (severe combined immunodeficiency disease), Status post bone marrow transplant
Hydralazine
A swab of one of the vesicular lesions was collected on 3/19/2025 and tested via PCR at facility. The specimen was forwarded to the Department of Health Public Health Lab for strain typing. The specimen was positive for vaccine-strain VZV. A bacterial culture was also performed but did not show any infection.